Dose response of ADX40-A20 vaccine in BALB/c mice. (A) Mice were immunized on day −28 and boosted on day −13 before challenge with A20 cells (day 0), as depicted in the immunization schedule. Tail-vein bleeds were performed on day −14 and −1, and the experimental end point was 60 days after challenge. (B) Mean (± SD) end point anti-Id titers after boost show increased levels at all doses of ADX40-A20 compared with PBS, as determined by ELISA (P < .0005). (C) Kaplan-Meier survival curve shows there was no significant survival advantage after inoculation with 20 or 50 μg of ADX40-A20. (D) Median survival was significantly increased using the lower doses (2.5 μg dose, P < .0005; 5 μg dose, P < .005; and 10 μg dose, P < .05).